NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.



Don't have an account? Subscribe

ADVERTISEMENT

ADVERTISEMENT

AstraZeneca have issued updated safety notice

By Mindo - 02nd Jun 2021

Doctor injecting vaccine into arm of senior male patient

The manufacturers of Vaxzevria, the Covid-19 AstraZeneca vaccine, have issued updated safety advice on the risk of thrombosis in combination with thrombocytopenia.

In a notice to healthcare professionals on 2 June, AstraZeneca advised that individuals diagnosed with thrombocytopenia within three weeks of vaccination with Vaxzevria should be “actively investigated for signs of thrombosis”.

“Similarly, individuals who present with thrombosis within three weeks of vaccination should be evaluated for thrombocytopenia.”

The notice outlined that the vaccine is contraindicated in individuals who have experienced thrombosis with Thrombocytopenia Syndrome (TTS) following vaccination with Vaxzevria.

“TTS requires specialised clinical management. Healthcare professionals should consult applicable guidance and/or consult specialists (e.g., haematologists, specialists in coagulation) to diagnose and treat this condition.”

Use of Vaxzevria was temporarily suspended here for a short time amid concerns about rare but serious blood clotting events.

The suspension was later lifted with advice that it be given to the over 60s only. Current advice from the National Immunisation Advisory Committee (NIAC) states that: “mRNA vaccines are preferable for those aged under 50 years including those with medical conditions with very high or high risk of severe Covid-19 disease”.

The European Medicines Agency (EMA) estimates that TTS occurs in 1/100,000 people vaccinated with Vaxzevria.

According to NIAC, Preliminary UK evidence suggests that the risk of TTS may not be higher and is possibly substantially lower (1.6/ million) after a second dose of Vaxzevria. 

“Although most cases have been reported in females, this may be because more women have been vaccinated. Some TTS cases have been reported in men and further analysis is required to determine any sex-related risk,” states NIAC advice.

The latest safety notice from AstraZeneca notes that a combination of thrombosis and thrombocytopenia, in some cases accompanied by bleeding, has been very rarely observed following vaccination with Vaxzevria.

“This includes severe cases presenting as venous thrombosis, including in unusual sites, such as cerebral venous sinus thrombosis and splanchnic vein thrombosis, as well as arterial thrombosis, concomitant with thrombocytopenia. Some cases had a fatal outcome. The majority of these cases occurred in the first three weeks following vaccination and occurred mostly in women under 60 years of age.”

Leave a Reply

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Latest Issue
The Medical Independent 11th June 2024

You need to be logged in to access this content. Please login or sign up using the links below.

ADVERTISEMENT

Most Read

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT